Gemcitabine in Ovarian Cancer

Phase II Study of Gemcitabine Plus Cisplatin as First-Line Therapy in Patients With Epithelial Ovarian Cancer

The primary endpoint of this study is to assess the objective tumor response rate in patients with advanced epithelial ovarian cancer receiving combination of Gemcitabine at a dose 1250 mg/m2 (Day 1 and 8) with Cisplatin 75 mg/m2 (Day 1) as first-line treatment

Inclusion Criteria:

• ECOG = 0-2
• Operated patients
• disease stage III-IV

Exclusion Criteria:

• No prior chemotherapy or radiation therapy